about
Tetraspanin CD81 is linked to ERK/MAPKinase signaling by Shc in liver tumor cellsA secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactionsPlatelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro.ADIPOQ rs266729 G/C gene polymorphism and plasmatic adipocytokines connect metabolic syndrome to colorectal cancerDifferential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE.Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC.The metastatic process: methodological advances and pharmacological challenges.Involvement of ADAMs in tumorigenesis and progression of hepatocellular carcinoma: Is it merely fortuitous or a real pathogenic link?PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors.Tetraspanin-enriched microdomains and hepatocellular carcinoma progression.Sorafenib: 10 years after the first pivotal trial.Lysophosphatidic acid receptor LPAR6 supports the tumorigenicity of hepatocellular carcinoma.Implications of the lysophosphatidic acid signaling axis in liver cancer.Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study.Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma.A systemic evolutionary approach to cancer: Hepatocarcinogenesis as a paradigm.Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans.Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells.The integrin, alpha6beta1, is necessary for the matrix-dependent activation of FAK and MAP kinase and the migration of human hepatocarcinoma cells.Frictional purpuric eruption associated with angiotensin II receptor blockers.Metabolic syndrome and Chronic Obstructive Pulmonary Disease (COPD): The interplay among smoking, insulin resistance and vitamin D.Correction: Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment.Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma.SCCA-IC serum levels are predictive of clinical response in HCV chronic hepatitis to antiviral therapy: a multicentric prospective study.PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma.The presence of clustered circulating tumor cells (CTCs) and circulating cytokines define an aggressive phenotype in metastatic colorectal cancerAutotaxin is a novel molecular identifier of type I endometrial cancerMoving the systemic evolutionary approach to cancer forward: Therapeutic implicationsTopology of the mitochondrial cAMP-dependent protein kinase and its substratesHepatic osteodystrophy in elderly: role of insulin-like growth factor-I and osteocalcinTetraspanins CD9 and CD81 are molecular partners of trimeric FcɛRI on human antigen-presenting cellsReply: To PMID 21674557Cell fusion promotes chemoresistance in metastatic colon carcinomaInfluence of plasminogen activator inhibitor-1 (SERPINE1) 4G/5G polymorphism on circulating SERPINE-1 antigen expression in HCC associated with viral infectionExpression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancerDrug reaction with eosinophilia and systemic symptoms caused by lenalidomideThe Systemic-Evolutionary Theory of the Origin of Cancer (SETOC): A New Interpretative Model of Cancer as a Complex Biological System
P50
Q24302000-12BE6998-D155-4DC9-81A2-371107B5964CQ28254145-13395BE0-B02D-47CF-803C-AEAA4CB3D8F2Q33412956-0BA5E262-9D99-4FE1-AC25-FC9EFBD9A88CQ33702331-F860FE98-B07D-4382-AB47-365EDC00E355Q34796473-238C059D-FCBC-4BBA-9604-68973C433367Q36037989-F62FDAD3-FF7E-460D-AF17-6E7462377871Q37218919-40D41D2A-2A82-4074-9520-1395DF90B5FCQ37481848-57D05CEE-1605-4BCF-8DA2-B699935C5F3BQ37701562-F04038BF-7D43-4A56-B40E-3EB93F741F93Q37951937-17A81207-8F42-4D70-979F-6382420D0C2EQ38214411-42BF44DA-B6FB-41DF-9CBC-BC5D27305845Q38544841-DA49A8C3-5D7A-4D60-8EA6-0B87335B0C92Q38919911-1753F18B-577B-453A-87E2-16C5639446FBQ39357912-025F447F-1D9B-4B00-A28E-00294E227D83Q39655391-E5E8626A-F6BE-47F4-97D1-60B283E8A068Q39939616-F5B8DCF6-A92E-452A-9E0B-65BBFB432D1FQ40669626-6A815296-3743-4C1E-8620-FA6BF8277D44Q42063388-AAFD772E-0029-4732-9AFB-654EBC13C2EDQ42820160-A80F35E8-E221-4B3E-931A-5115523395BBQ43657675-675E3579-90AB-41B0-9A1B-6A1DC288443DQ44551243-E1C3FD2D-D7B5-4989-8B11-82163DB90158Q45793325-68F739FB-55C3-433A-81A7-D330318D1387Q45895736-FCF1A96C-C04C-4887-83C2-3D9A477B626CQ47805446-0845B5A8-66EC-4B88-8C13-D402C08C9A10Q48413974-2070C6D7-D3C3-4A00-AEA5-B893834B7278Q50099297-7452E9AB-C614-4959-A1E4-AF3688B6E73FQ50551137-B1A6A2D1-7A6F-485B-954C-B54D5ECEAE34Q53229616-0BD3D1F3-676E-4F93-87B3-CAB83649302BQ57602278-59D2EE59-CEA3-45C6-93ED-ED8920C793B4Q58105355-063C16A3-338E-4272-9F95-2AB4A03B416AQ58550868-1F704DC6-8D54-42E6-9FFD-93FD87BBD84BQ71771837-549AE904-BB4A-4952-A2EB-3533B8CE70B0Q73570542-67E19F50-53AA-4F72-A09C-7680CE62BC0AQ83221150-2CAB48A9-A150-4DF1-884E-BDED37E66C9BQ84395699-37F97ECC-8D16-4629-8124-56CD411426C2Q84507421-3FF4BB97-AD9A-4029-AC92-FEC5B8374159Q84575360-C67F7496-31D6-438E-8193-55EB67E708C5Q85189998-3738F18B-77B9-41D2-8C23-172D07C79B89Q85395949-94D64A40-CAC7-465F-B996-14BF50EA9173Q90461191-F26E8E4A-F0B4-4E29-8F33-7DB173DB877A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Antonio Mazzocca
@ast
Antonio Mazzocca
@en
Antonio Mazzocca
@es
Antonio Mazzocca
@nl
type
label
Antonio Mazzocca
@ast
Antonio Mazzocca
@en
Antonio Mazzocca
@es
Antonio Mazzocca
@nl
prefLabel
Antonio Mazzocca
@ast
Antonio Mazzocca
@en
Antonio Mazzocca
@es
Antonio Mazzocca
@nl
P106
P21
P31
P496
0000-0003-0940-7352